Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

Published:2023-05-15 Issue:6 Volume:29 Page:1379-1388
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Heczey Andras^ORCID,Xu Xin^ORCID,Courtney Amy N.^ORCID,Tian Gengwen,Barragan Gabriel A.,Guo Linjie,Amador Claudia Martinez^ORCID,Ghatwai Nisha,Rathi Purva,Wood Michael S.,Li Yanchuan,Zhang Chunchao,Demberg Thorsten,Di Pierro Erica J.,Sher Andrew C.,Zhang Huimin,Mehta Birju,Thakkar Sachin G.^ORCID,Grilley Bambi,Wang Tao^ORCID,Weiss Brian D.^ORCID,Montalbano Antonino,Subramaniam Meena,Xu Chenling,Sachar Chirag,Wells Daniel K.^ORCID,Dotti Gianpietro,Metelitsa Leonid S.^ORCID

Funder

Alex’s Lemonade Stand Foundation for Childhood Cancer

St. Baldrick’s Foundation

American Cancer Society

Texas Children’s Hospital

Athenex, Inc.

Baylor College of Medicine

Cincinnati Children’s Hospital Medical Center

Immunai, Inc

Immunai, Inc.

UNC | UNC-Chapel Hill | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-023-02363-y.pdf

Reference56 articles.

1. Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341–1355 (2019).

2. Batra, S. A. et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol. Res. 8, 309–320 (2020).

3. Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).

4. Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).

5. Heczey, A. et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124, 2824–2833 (2014).

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GD2 targeting CAR T cells for neuroblastoma;EJC Paediatric Oncology;2024-12

2. Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment;Current Pharmaceutical Biotechnology;2024-11

3. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors;Cytotherapy;2024-09

4. Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances;Best Practice & Research Clinical Haematology;2024-09

5. Bioactive sphingolipids as emerging targets for signal transduction in cancer development;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3